45TiP - Clinico-pathological evaluation of alloimunization in breast cancer patients receiving multiple transfusions

Date 05 November 2016
Event ESMO Symposium on Immuno-Oncology 2016
Session Lunch and general poster viewing
Presenter Ambreen Sheikh
Citation Annals of Oncology (2016) 27 (suppl_8): viii4-viii17. 10.1093/annonc/mdw527
Authors A. Sheikh1, S.A. Ali2
  • 1Pathology, Dow University of Health Sciences, 17500 - Karachi/PK
  • 2Pathology, Dow University of Health Sciences, Karachi/PK

Abstract

Aim/Background

The development of alloantibodies against RBCs antigens can decrease the half-life of RBC of recipient and delayed hemolytic transfusion reactions. Need is to analyze the developed alloantibodies in breast cancer patients which are supposed to have low immunity levels due to exposure to immunosuppressive drugs or radiotherapies. Differences in immunization risks depend upon a number of factors including genetic makeover and RBC phenotype. Since Pakistan has a different ethnicity, climate and nutritional status from western population hence there is a dire need to conduct such studies. Purpose of this study is to detect the developed alloantibodies in multiple transfused breast cancer patients undergoing chemotherapy or radiotherapy.

Trial design

Research design: A case-control study. Sample description: By taking a previously published study which showed 55% presence of alloantibodies, our calculated sample size with the help of PASS online software sample size will be 96 patients with 95% confidence interval and 10% chances of error. 23 patients with multiple transfusions and no cancer history will be taken as controls. Required number of patients will be selected with the help of Dow Lab Screening and identification with the help of panel cells will be performed in Dow Research Institute of Biotechnology and Biomedical Sciences (DRIBS). Statistical analysis: Multivariate statistical technique will be used for the analysis of the data. Statistical Package for Social Sciences software version16 will be used to generate descriptive statistics and inferential tests. Methodology: An antibody screening test will have to be performed using a 3 panel cell followed by an antibody identification test for positive ones with the help of commercial 11 cell panel.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Dow University

Disclosure

All authors have declared no conflicts of interest.